Invention Grant
US09389233B2 TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
有权
TET2作为造血肿瘤中的诊断和代词标记
- Patent Title: TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
- Patent Title (中): TET2作为造血肿瘤中的诊断和代词标记
-
Application No.: US12997203Application Date: 2009-06-12
-
Publication No.: US09389233B2Publication Date: 2016-07-12
- Inventor: Franck Viguie , Olivier Bernard , Michaela Fontenay , Christian Bastard , Francois Delhommeau , William Vainchenker
- Applicant: Franck Viguie , Olivier Bernard , Michaela Fontenay , Christian Bastard , Francois Delhommeau , William Vainchenker
- Applicant Address: FR Paris FR Villejuif FR Paris FR Rouen FR Paris FR Paris FR Orsay
- Assignee: Institute National de la Sante et de la Recherche Medicale (Inserm),Institut Gustave-Roussy,Assistance Publique-Hopitaux de Paris,Centre Henri Becquerel,Universite Paris Descartes,Universite Pierre et Marie Curie (PARIS 6),Universite Paris-Sud
- Current Assignee: Institute National de la Sante et de la Recherche Medicale (Inserm),Institut Gustave-Roussy,Assistance Publique-Hopitaux de Paris,Centre Henri Becquerel,Universite Paris Descartes,Universite Pierre et Marie Curie (PARIS 6),Universite Paris-Sud
- Current Assignee Address: FR Paris FR Villejuif FR Paris FR Rouen FR Paris FR Paris FR Orsay
- Agency: Foley & Lardner LLP
- Priority: EP08305255 20080612; EP09155169 20090313
- International Application: PCT/EP2009/057295 WO 20090612
- International Announcement: WO2009/150229 WO 20091217
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/574
Abstract:
The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.
Public/Granted literature
- US20110263523A1 TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS Public/Granted day:2011-10-27
Information query
